万达生物制药提交生物制剂许可证申请给FDA,申请用于治疗广义脓疱型银屑病的Imsidolimab
万达生物制药提交生物制剂许可证申请给FDA,申请用于治疗广义脓疱型银屑病的Imsidolimab
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.